Strategic Partnerships NorthStar is actively forming multi-year collaborations with industry and research groups (Zeno Power, LIFT, QSA Global, BIOEMTECH) to secure supply, development, and commercialization of radiopharmaceuticals and actinium-225, presenting several cross-selling and channel partner opportunities for contract manufacturing, supply chain integration, and joint development programs.

Manufacturing Scale The company operates a growing commercial-scale production footprint, including a 52,000 sq ft advanced manufacturing center and plans to expand Cu-67 and Ac-225 capabilities, creating opportunities to position our equipment, containment, and process automation solutions for heavy radiopharmaceutical manufacturing and quality systems.

Technical Capabilities NorthStar uses first-in-kind electron accelerator technology and NCa Ac-225 production, alongside ISO 13485 compliance and a tech stack supporting collaboration (HubSpot, TeamViewer, OCaml, Python). This suggests opportunities for process optimization tools, GMP-compliant software, data analytics, and remote service offerings.

Commercial CMDO With a dedicated Radiopharmaceutical CMDO/CMO unit that accelerates development and commercialization for biopharma partners, there is potential to pitch end-to-end development services, regulatory support, and scalable manufacturing partnerships to CROs and biotech firms pursuing radiopharmaceutical programs.

Growth & Funding Signals Recent high-profile partnerships, leadership additions (Chief Commercial Officer), and active fundraising indicate ongoing growth and market demand for radiopharmaceuticals; sales conversations could focus on capacity guarantees, supply security, and long-term collaboration terms for key customers seeking reliable actinium-225 and copper-67 supply.